Which lab markers are typically assessed in the endocrine evaluation after menopause?

In the assessment of endocrine function after menopause, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are the primary lab markers evaluated. After menopause, the ovaries significantly reduce their production of estrogens and other sex hormones, leading to changes in the hypothalamic-pituitary-gonadal axis.

As a result, FSH and LH levels rise due to decreased negative feedback from estrogen and progesterone. This hormonal elevation is a typical response as the body attempts to stimulate the underactive ovaries. Monitoring FSH and LH helps to confirm the transition into menopause and assess the degree of hormonal change occurring in the body.

In contrast, other markers like estradiol and progesterone are not typically assessed post-menopause because their levels generally decrease significantly after ovarian function ceases. Anti-Müllerian hormone (AMH) and inhibin B are more relevant to ovarian reserve and function, which are not applicable after menopause. Additionally, while testosterone and cortisol levels have their significance, they are not primary markers used in the evaluation specifically to confirm menopause and its related endocrine changes.